1. Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center
- Author
-
Bosso L, Cordonnier J, Olivier Pantet, Noémie Boillat-Blanco, Pierre-Nicolas Carron, Jean-Yves Meuwly, Mary-Anne Hartley, Thomas Brahier, Schaad S, Espejo T, and Olivier Hugli
- Subjects
Adult ,medicine.medical_specialty ,COVID-19/diagnostic imaging ,Humans ,Lung/diagnostic imaging ,Outpatients ,Point-of-Care Systems ,Prospective Studies ,SARS-CoV-2 ,Switzerland/epidemiology ,Ultrasonography/methods ,COVID-19 ,diagnostic radiology ,infectious diseases ,ultrasonography ,Logistic regression ,Internal medicine ,pneumonia ,Medicine ,Prospective cohort study ,Lung ,Point of care ,Ultrasonography ,ultrasound ,business.industry ,disease 2019 covid-19 ,Emergency department ,sensitivity ,medicine.disease ,Pneumonia ,Cohort ,Population study ,Observational study ,business ,Switzerland - Abstract
BackgroundEarly identification of SARS-CoV-2 infection is important to guide quarantine and reduce transmission. This study evaluates the diagnostic performance of lung ultrasound (LUS), an affordable, consumable-free point-of-care tool, for COVID-19 screening.MethodsThis prospective observational cohort included adults presenting with cough and/or dyspnea at a SARS-CoV-2 screening center of Lausanne University Hospital between March 31st and May 8th, 2020. Investigators recorded standardized LUS images and videos in 10 lung zones per subject. Two blinded independent experts reviewed LUS recording and classified abnormal findings according to pre-specified criteria to investigate their predictive value to diagnose SARS-CoV-2 infection according to PCR on nasopharyngeal swabs (COVIDpos vs COVIDneg). We finally combined LUS and clinical findings to derive a multivariate logistic regression diagnostic score.ResultsOf 134 included patients, 23% (n=30/134) were COVIDpos and 77% (n=103/134) were COVIDneg; 85%, (n=114/134) cases were previously healthy healthcare workers presenting within 2 to 5 days of symptom onset (IQR). Abnormal LUS findings were significantly more frequent in COVIDpos compared to COVIDneg (45% versus 26%, p=0.045) and mostly consisted of focal pathologic B-lines. Combining LUS findings in a multivariate logistic regression score had an area under the receiver-operating curve of 63.9% to detect COVID-19, but improved to 84.5% with the addition of clinical featuresConclusionsCOVIDpos patients are significantly more likely to have lung pathology by LUS. Our findings have potential diagnostic value for COVID-19 at the point of care. Combination of clinical and LUS features showed promising results, which need confirmation in a larger study population.What is already known on the subjectLung ultrasonography (LUS) is a consumable-free, easy-to-use, portable, non-radiating and non-invasive screening tool that can be performed at the bedside: its diagnostic performance for pneumonia has been established.Recent studies conducted in emergency department showed a correlation between LUS findings and COVID-19 diagnosis.What the study adsThis is the first study assessing the diagnostic performance of LUS for COVID-19 in outpatients with mild acute respiratory tract infection.Mild COVID-19 patients are more likely to have lung pathology by LUS compared with COVID-19 negative.Combination of clinical and LUS features showed promising results with a potential diagnostic value for COVID-19 at the point of care.
- Published
- 2022